FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385666989> ?p ?o ?g. }

• W4385666989 endingPage "e855292a" @default.
• W4385666989 startingPage "e855292a" @default.
• W4385666989 abstract "Topic: 3. Acute myeloid leukemia - Biology & Translational Research Background: Myeloid cell leukemia-1 (Mcl-1), an inhibitor of apoptosis, is overexpressed in acute myeloid leukemia (AML). Despite the availability of numerous treatments in clinical settings, efficient approaches are still needed for the treatment of AML. Small molecule inhibitor, S63845, specifically binds to Mcl-1 and inhibits cell proliferation in AML cells. However, the exact mechanism of S63845 in AML cells remains unknown. Tumor cells have been found to have altered lipid compositions, which can impact their response to various agents. Bioactive sphingolipids play a crucial role in various cellular processes. Sphingolipid signaling pathways are important in tumor immunology by controlling the anti-tumor abilities of immune cells. Sphingosine-1-P triggers pro-inflammatory signals, while the inhibition of sphingosine kinase-1 activity leads to a reduction of sphingosine-1-P, resulting in enhanced efficiency of immunotherapy. Despite of some studies on the effects of Mcl-1 on inflammation, little is known about the effects on tumor immunity and cancer-related inflammation. Aims: The goal of this study was to investigate the impact of the Mcl-1 inhibitor, S63845, on lipid profiles in AML cell lines with a specific emphasis on sphingolipids, and to explore its effects on the expression levels of the genes involved in tumor immunity and cancer-related inflammation as well as to propose a link between the Mcl-1, sphingolipids, and tumor immunity. Methods: The cytotoxicity of S63845 was determined in three different AML cell lines (MV4-11, HL60, KG1) by MTT cell proliferation assay. The lipidome was analyzed by quantitative shotgun lipidomics, which analyzed 378 individual lipid species from 26 classes in the major lipid categories. The differential expression data from GEO datasets through NCBI were analyzed by GEO2R to compare the expression levels of MCL1, ceramide synthase (CERS) genes and the genes involved in tumor immunity and cancer-related inflammation from PBMC samples of AML patients and healthy individuals. Results: The IC50 values for S63845 were determined to be 7 nM for MV4-11, 53 nM for HL60, and 479 nM for KG1 cell lines. The lipidome results showed that S63845 treatment caused an increase in ceramide (Cer) levels in MV4-11 and KG1, while reducing downstream sphingolipids. Conversely, in HL60 cell lines, S63845 treatment led to an increase in hexosylceramide (HexCer) levels, with decreases in Cer and sphingomyelin (SM). Analysis of GEO datasets revealed that expression levels of MCL1, and the genes including IL10, LAMP3, and RGS1, related to the activation of cancer-related inflammation, are higher in AML patient samples as compared to the healthy individuals. However, expression levels of CERS1 and CERS2 genes, and the genes including TICAM1, TICAM2, SOCS7, and CD53, related to the activation of tumor immunity, are found lower in AML patient samples. Summary/Conclusion: The findings of this study suggest that S63845 may reduce cell proliferation by modulating the lipid compositions, especially, by increasing ceramide levels in AML cell lines. Additionally, the study highlights that S63845 has a distinct impact on the lipid profiles of different AML cell lines, indicating the potential of using lipidomic profiles as markers. Importantly, our study proposes that the increases in Cer levels in response to S63845 treatment may occur due to SM hydrolysis and may be linked to the anti-inflammatory effects of S63845 in AML cell lines, which deserve further investigation to fully understand the specific mechanisms. Keywords: Mcl-1, Acute promyelocytic leukemia, Lipid metabolism, Acute myeloid leukemia" @default.
• W4385666989 created "2023-08-09" @default.
• W4385666989 creator A5025555314 @default.
• W4385666989 creator A5056571521 @default.
• W4385666989 date "2023-08-01" @default.
• W4385666989 modified "2023-09-27" @default.
• W4385666989 title "PB1793: MCL-1 INHIBITION AFFECTS LIPIDOME WHICH MAY BE LINKED TO TUMOR IMMUNITY AND CANCER-RELATED INFLAMMATION IN ACUTE MYELOID LEUKEMIA" @default.
• W4385666989 doi "https://doi.org/10.1097/01.hs9.0000974028.85529.2a" @default.
• W4385666989 hasPublicationYear "2023" @default.
• W4385666989 type Work @default.
• W4385666989 citedByCount "0" @default.
• W4385666989 crossrefType "journal-article" @default.
• W4385666989 hasAuthorship W4385666989A5025555314 @default.
• W4385666989 hasAuthorship W4385666989A5056571521 @default.
• W4385666989 hasBestOaLocation W43856669891 @default.
• W4385666989 hasConcept C121608353 @default.
• W4385666989 hasConcept C170493617 @default.
• W4385666989 hasConcept C203014093 @default.
• W4385666989 hasConcept C2776596873 @default.
• W4385666989 hasConcept C2776914184 @default.
• W4385666989 hasConcept C2777700496 @default.
• W4385666989 hasConcept C2778461978 @default.
• W4385666989 hasConcept C2778703144 @default.
• W4385666989 hasConcept C2778729363 @default.
• W4385666989 hasConcept C2779282312 @default.
• W4385666989 hasConcept C502942594 @default.
• W4385666989 hasConcept C54355233 @default.
• W4385666989 hasConcept C55493867 @default.
• W4385666989 hasConcept C61705674 @default.
• W4385666989 hasConcept C86803240 @default.
• W4385666989 hasConcept C8891405 @default.
• W4385666989 hasConcept C95444343 @default.
• W4385666989 hasConcept C96232424 @default.
• W4385666989 hasConceptScore W4385666989C121608353 @default.
• W4385666989 hasConceptScore W4385666989C170493617 @default.
• W4385666989 hasConceptScore W4385666989C203014093 @default.
• W4385666989 hasConceptScore W4385666989C2776596873 @default.
• W4385666989 hasConceptScore W4385666989C2776914184 @default.
• W4385666989 hasConceptScore W4385666989C2777700496 @default.
• W4385666989 hasConceptScore W4385666989C2778461978 @default.
• W4385666989 hasConceptScore W4385666989C2778703144 @default.
• W4385666989 hasConceptScore W4385666989C2778729363 @default.
• W4385666989 hasConceptScore W4385666989C2779282312 @default.
• W4385666989 hasConceptScore W4385666989C502942594 @default.
• W4385666989 hasConceptScore W4385666989C54355233 @default.
• W4385666989 hasConceptScore W4385666989C55493867 @default.
• W4385666989 hasConceptScore W4385666989C61705674 @default.
• W4385666989 hasConceptScore W4385666989C86803240 @default.
• W4385666989 hasConceptScore W4385666989C8891405 @default.
• W4385666989 hasConceptScore W4385666989C95444343 @default.
• W4385666989 hasConceptScore W4385666989C96232424 @default.
• W4385666989 hasIssue "S3" @default.
• W4385666989 hasLocation W43856669891 @default.
• W4385666989 hasLocation W43856669892 @default.
• W4385666989 hasOpenAccess W4385666989 @default.
• W4385666989 hasPrimaryLocation W43856669891 @default.
• W4385666989 hasRelatedWork W1553203461 @default.
• W4385666989 hasRelatedWork W2003007879 @default.
• W4385666989 hasRelatedWork W2012206449 @default.
• W4385666989 hasRelatedWork W2061137389 @default.
• W4385666989 hasRelatedWork W2155525241 @default.
• W4385666989 hasRelatedWork W2406937849 @default.
• W4385666989 hasRelatedWork W3011428406 @default.
• W4385666989 hasRelatedWork W3167882470 @default.
• W4385666989 hasRelatedWork W4243027891 @default.
• W4385666989 hasRelatedWork W4385666989 @default.
• W4385666989 hasVolume "7" @default.
• W4385666989 isParatext "false" @default.
• W4385666989 isRetracted "false" @default.
• W4385666989 workType "article" @default.